Short answer
Sana Biotechnology, Inc. (SANA) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Sana Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the detailed results
- Investor focus: cash position, operating expenses, R&D spending, and development-program progress
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss improved to $63.6M, or $0.22 per share, from $93.8M, benefiting from no 2025 impairment charge
- Cash, equivalents, and marketable securities reached $160.5M, supported by $93.3M financing proceeds and providing runway into mid-2027
- Mayo Clinic invested $25.0M in equity, adding strategic validation and funding for SC451 development
- SC451 and SG293 could enter Phase 1/2 studies as early as 2026, creating near-term clinical catalysts but execution and regulatory risk
- Six-month non-GAAP operating cash burn was $69.3M, while contingent consideration and success-payment liabilities rose to $175.3M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sana Biotechnology, Inc. 8-K filings
Get the next SANA 8-K as it lands
Follow SANA for push alerts, or ask the research agent what this filing means.